DADC
BIO icon

D.A. Davidson & Co’s Bio-Rad Laboratories Class A BIO Stock Holding History

D.A. Davidson & Co’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-414
Closed -$75K – 2337
2016
Q4 		$75K Sell
414
-8
-2% -$1.36K ﹤0.01% 1429
2016
Q3 		$68K Hold
422
– – ﹤0.01% 1387
2016
Q2 		$59K Hold
422
– – ﹤0.01% 1348
2016
Q1 		$57K Buy
422
+1
+0.2% +$131 ﹤0.01% 1338
2015
Q4 		$58K Sell
421
-51
-11% -$7.07K ﹤0.01% 1341
2015
Q3 		$63K Sell
472
-102
-18% -$14.7K ﹤0.01% 1268
2015
Q2 		$86K Sell
574
-114
-17% -$16.3K ﹤0.01% 1208
2015
Q1 		$93K Buy
688
+1
+0.1% +$124 ﹤0.01% 1168
2014
Q4 		$82K Buy
687
+79
+13% +$9.09K ﹤0.01% 1216
2014
Q3 		$68K Sell
608
-1,280
-68% -$152K ﹤0.01% 1283
2014
Q2 		$225K Sell
1,888
-64
-3% -$7.82K 0.01% 852
2014
Q1 		$249K Buy
1,952
+43
+2% +$5.51K 0.01% 800
2013
Q4 		$234K Sell
1,909
-132
-6% -$16.1K 0.01% 782
2013
Q3 		$239K Buy
2,041
+151
+8% +$17.8K 0.01% 654
2013
Q2 		$210K Buy
+1,890
New +$222K 0.01% 659

Other funds holding BIO

ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CM
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

D.A. Davidson & Co's BIO Position: Q1 2017 in Review

D.A. Davidson & Co sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2017, closing a stake of 414 shares — an estimated $75K sold.

D.A. Davidson & Co first reported a position in BIO in Q2 2013 and held it in 15 quarters. The position peaked at $249K in Q1 2014. 274 funds tracked by Wall St. Rank hold BIO as of Q1 2017.

  • D.A. Davidson & Co reported no remaining Bio-Rad Laboratories Class A position as of Q1 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 414 Bio-Rad Laboratories Class A shares in Q1 2017, an estimated $75K.
  • D.A. Davidson & Co first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 15 quarters.
  • D.A. Davidson & Co's Bio-Rad Laboratories Class A position peaked at $249K in Q1 2014.
  • 274 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2017.

Based on D.A. Davidson & Co's 13F filing for Q1 2017, filed 12 May 2017.